(Q38994795)

English

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

scientific article published on 24 January 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

8 September 2017

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial (English)

1 reference

Europe PubMed Central

8 September 2017

phase III clinical trial

0 references

multicenter clinical trial

0 references

pancreatic cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

David Cunningham

9

1 reference

Europe PubMed Central

8 September 2017

object named as

Pascal Hammel

31

0 references

John P Neoptolemos

object named as

John P Neoptolemos

1

0 references

Bengt Glimelius

16

object named as

Bengt Glimelius

1 reference

Europe PubMed Central

8 September 2017

Markus Büchler

34

object named as

Markus W Büchler

1 reference

Europe PubMed Central

8 September 2017

32

object named as

Thilo Hackert

1 reference

Europe PubMed Central

8 September 2017

Jakob R Izbicki

18

object named as

Jakob R Izbicki

1 reference

Europe PubMed Central

8 September 2017

Christopher Halloran

6

object named as

Christopher M Halloran

1 reference

Europe PubMed Central

8 September 2017

author name string

Daniel H Palmer

2

1 reference

Europe PubMed Central

8 September 2017

Paula Ghaneh

3

1 reference

Europe PubMed Central

8 September 2017

Eftychia E Psarelli

4

1 reference

Europe PubMed Central

8 September 2017

Juan W Valle

5

1 reference

Europe PubMed Central

8 September 2017

Olusola Faluyi

7

1 reference

Europe PubMed Central

8 September 2017

Derek A O'Reilly

8

1 reference

Europe PubMed Central

8 September 2017

Jonathan Wadsley

10

1 reference

Europe PubMed Central

8 September 2017

Suzanne Darby

11

1 reference

Europe PubMed Central

8 September 2017

Tim Meyer

12

1 reference

Europe PubMed Central

8 September 2017

Roopinder Gillmore

13

1 reference

Europe PubMed Central

8 September 2017

Alan Anthoney

14

1 reference

Europe PubMed Central

8 September 2017

Pehr Lind

15

1 reference

Europe PubMed Central

8 September 2017

Stephen Falk

17

1 reference

Europe PubMed Central

8 September 2017

Gary William Middleton

19

1 reference

Europe PubMed Central

8 September 2017

Sebastian Cummins

20

1 reference

Europe PubMed Central

8 September 2017

Paul J Ross

21

1 reference

Europe PubMed Central

8 September 2017

Harpreet Wasan

22

1 reference

Europe PubMed Central

8 September 2017

Alec McDonald

23

1 reference

Europe PubMed Central

8 September 2017

Tom Crosby

24

1 reference

Europe PubMed Central

8 September 2017

Yuk Ting Ma

25

1 reference

Europe PubMed Central

8 September 2017

Kinnari Patel

26

1 reference

Europe PubMed Central

8 September 2017

David Sherriff

27

1 reference

Europe PubMed Central

8 September 2017

Rubin Soomal

28

1 reference

Europe PubMed Central

8 September 2017

David Borg

29

1 reference

Europe PubMed Central

8 September 2017

Sharmila Sothi

30

1 reference

Europe PubMed Central

8 September 2017

Richard Jackson

33

1 reference

Europe PubMed Central

8 September 2017

European Study Group for Pancreatic Cancer

35

1 reference

Europe PubMed Central

8 September 2017

language of work or name

0 references

publication date

24 January 2017

1 reference

Europe PubMed Central

8 September 2017

full work available at URL

http://eprints.whiterose.ac.uk/111480

content deliverer

White Rose Research Online

object has role

published version

1 reference

White Rose Research Online

http://eprints.whiterose.ac.uk/111480

15 December 2018

1 reference

Europe PubMed Central

8 September 2017

389

1 reference

Europe PubMed Central

8 September 2017

10073

1 reference

Europe PubMed Central

8 September 2017

1011-1024

1 reference

Europe PubMed Central

8 September 2017

Pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932409-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932409-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932409-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Meta-Analyses of Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932409-6

7 January 2021

based on heuristic

inferred from DOI database lookup

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932409-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932409-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932409-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932409-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932409-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932409-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932409-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Bayesian analysis unravels pancreas-cancer adjuvant therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932409-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932409-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1 mm of a resection margin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932409-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Asymptotically Efficient Rank Invariant Test Procedures

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932409-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Multiple imputation using chained equations: Issues and guidance for practice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932409-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A new look at the statistical model identification

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932409-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A note on quantifying follow-up in studies of failure time

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932409-6

7 January 2021

based on heuristic

inferred from DOI database lookup

TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932409-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Joint modelling of longitudinal measurements and event time data.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932409-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932409-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932409-6

7 January 2021

based on heuristic

inferred from DOI database lookup

First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932409-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932409-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932409-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932409-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(16)32409-6

1 reference

Europe PubMed Central

8 September 2017

10.1016/S0140-6736(16)32409-6

0 references

0 references

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

8 September 2017

2-s2.0-85011349966

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38994795&oldid=1801195898"